Impact of the expanded label for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del variant in the USA
Extension of the ETI label to rare <i>CFTR</i> variants is associated with meaningful improvements in lung function and a marked reduction in pulmonary exacerbations.
Authors
- Don B. Sanders (ORCID: https://orcid.org/0000-0001-6265-6249)
- Elizabeth A. Cromwell (ORCID: https://orcid.org/0000-0002-5106-0607)
- Rhonda D. Szczesniak (ORCID: https://orcid.org/0000-0003-0705-715X)
- Wayne J. Morgan (ORCID: https://orcid.org/0000-0002-6346-8140)
- J. Ostrenga
- Pierre‐Régis Burgel (ORCID: https://orcid.org/0000-0003-0903-9828)
- Carlo Castellani (ORCID: https://orcid.org/0000-0003-1916-0963)
Institutions
- Cincinnati Children's Hospital Medical Center (US)
- University of Arizona (US)
- Inserm (FR)
- Université Paris Cité (FR)
- Cystic Fibrosis Foundation (US)
- Istituto Giannina Gaslini (IT)
- Riley Hospital for Children (US)
- Hôpital Cochin (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Laboratoire National de Référence (MA)
- Institut Cochin (FR)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Indiana University School of Medicine
- Arizona State University (US)
- Indiana University – Purdue University Indianapolis (US)
- University of Cincinnati (US)
Publication Details
- Journal
- European Respiratory Journal
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1183/13993003.01146-2024
- Citations
- 14
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 5.87
Funders
- Cystic Fibrosis Foundation
- AstraZeneca
- Sanofi
- Insmed
- National Institutes of Health
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases